# Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma

> **NCT04871334** · PHASE1 · UNKNOWN · sponsor: **Shandong TheraWisdom Biopharma Co., Ltd.** · enrollment: 76 (estimated)

## Conditions studied

- Advanced Melanoma
- Advanced Urothelial Carcinoma

## Interventions

- **DRUG:** TWP-101

## Key facts

- **NCT ID:** NCT04871334
- **Lead sponsor:** Shandong TheraWisdom Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-07
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2021-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04871334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04871334, "Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04871334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*